Bank of New York Mellon
NRXP icon

Bank of New York Mellon’s NRX Pharmaceuticals NRXP Stock Holding History

Bank of New York Mellon’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,013
Closed -$4.78K – 4222
2024
Q1 		$4.78K Hold
1,013
– – ﹤0.01% 4139
2023
Q4 		$4.66K Hold
1,013
– – ﹤0.01% 4289
2023
Q3 		$2.63K Hold
1,013
– – ﹤0.01% 4335
2023
Q2 		$4.9K Hold
1,013
– – ﹤0.01% 4370
2023
Q1 		$6.68K Hold
1,013
– – ﹤0.01% 4374
2022
Q4 		$11.2K Hold
1,013
– – ﹤0.01% 4416
2022
Q3 		$7K Hold
1,013
– – ﹤0.01% 4523
2022
Q2 		$6K Hold
1,013
– – ﹤0.01% 4570
2022
Q1 		$25K Buy
+1,013
New +$33K ﹤0.01% 4604

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of New York Mellon's NRXP Position: Q2 2024 in Review

Bank of New York Mellon sold out of NRX Pharmaceuticals (NRXP) in Q2 2024, closing a stake of 1,013 shares — an estimated $4.78K sold.

Bank of New York Mellon first reported a position in NRXP in Q1 2022 and held it in 9 quarters. The position peaked at $25K in Q1 2022. 19 funds tracked by Wall St. Rank hold NRXP as of Q2 2024.

  • Bank of New York Mellon reported no remaining NRX Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 1,013 NRX Pharmaceuticals shares in Q2 2024, an estimated $4.78K.
  • Bank of New York Mellon first reported a position in NRX Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Bank of New York Mellon's NRX Pharmaceuticals position peaked at $25K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.